Optaflu

Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.

History

On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.^[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.^[2]

References

^ "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29.
^ Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29. But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases. {{cite news}}: Cite has empty unknown parameter: |coauthors= (help)

[1] "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29.

[2] Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29. But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases. {{cite news}}: Cite has empty unknown parameter: |coauthors= (help)

[1]

[2]